High resolution retinal maps aid disease diagnoses
Posted: 6 February 2025 Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes, dementia and multiple sclerosis.…
Cell Bauhaus receives $3 million grant for digital twin research into cell behaviour
Posted: 6 February 2025 University of Melbourne affiliated startup Cell Bauhaus has received a $3 million grant from the Gates Foundation (formerly the Bill & Melinda Gates Foundation) to continue their work utilising digital twins to investigate how…
Australia’s TGA Approves Registration of CSL’s ANDEMBRY for the Prevention of Recurrent Hereditary Angioedema Attacks
Posted: 5 February 2025 Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the Australian Therapeutic Goods Administration (TGA) has approved the registration of ANDEMBRY® (garadacimab) for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12…
Amplia completes recruitment of ACCENT Trial
Posted: 5 February 2025 Amplia has today announced that it has completed the planned enrolment of the ACCENT Phase 2a clinical trial. The two-stage ACCENT trial is investigating the use of the Company’s best-in-class FAK inhibitor narmafotinib in…
Investing In Medtech So Patients Can Breathe Easier
Posted: 5 February 2025 The Allan Labor Government is backing local medical technology startup Diag-Nose Medical to develop new treatments for chronic respiratory disorders, which has the potential to help millions of people worldwide. Minister for Economic Growth and…
Optiscan kicks off GI study in Germany with first imaging prototype
Posted: 5 February 2025 Optiscan has been featured in Stockhead, The Australian, and 11 News Corp mastheads following the announcement of its pre-clinical gastrointestinal (GI) study in Germany. The piece explores how Optiscan’s first flexible GI imaging prototype…
Alterity Therapeutics Announces Funding to Accelerate ATH434 Clinical and Business Development Activities
Posted: 5 February 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it raised capital in the U.S. to accelerate clinical development…
Phrenix secures major funding boost from US and Australian venture capital firms to advance new therapeutics for psychiatric disorders
Posted: 5 February 2025 Phrenix Therapeutics, a cutting-edge biotech company focused on next-generation medicines for psychiatric and neurological disorders, has secured significant seed investment from specialist biotech venture capital firms Curie.Bio (US) and Brandon Capital (Australia). Founded in 2022, Phrenix Therapeutics is…
IMPROVING CANCER OUTCOMES BY BACKING OUR RESEARCHERS
Posted: 5 February 2025 The Allan Labor Government is backing Victoria’s world-class cancer researchers, delivering $2.7 million to improve cancer outcomes and save lives across the state. Marking World Cancer Day, Minister for Health Mary-Anne Thomas today announced…
$11 million to build and grow on Australian research in climate change and health
Posted: 31 January 2025 A TCR is a one-time request for grant applications to address a specific health issue where there is significant research knowledge gap or unmet need. TCRs are designed to stimulate research or build research…
Blood immune cells could hold key to showing disease progression in Parkinson’s
Posted: 31 January 2025 A new discovery in blood immune cells has put researchers one step closer to identifying a blood biomarker that would allow doctors to personalise treatments for Parkinson’s disease. In a multi-disciplinary effort, researchers from the…
Researchers discover how cigarette smoke impairs critical lung immune cells
Posted: 31 January 2025 Cigarette smoking is widespread and deadly, yet our understanding of how cigarette smoke actually causes serious respiratory illnesses in incomplete, which has severely hampered the development of effective treatments. In the Journal of Experimental Medicine (JEM)…
